Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1410468
European Journal of Endocrinology, Vol 141, Issue 5, 468-474
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niccoli-Sire, P
Right arrow Articles by Conte-Devolx, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niccoli-Sire, P
Right arrow Articles by Conte-Devolx, B

Articles

Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC)

P Niccoli-Sire, A Murat, E Baudin, JF Henry, C Proye, JC Bigorgne, B Bstandig, E Modigliani, S Morange, M Schlumberger, and B Conte-Devolx

Services d'Endocrinologie et de Chirurgie Endocrinienne, CHU Timone, Marseille, France. pnicoli-sire@ap-hm.fr

BACKGROUND: Once genetic testing accurately identifies MEN 2 gene carriers, affected children are given the opportunity to undergo thyroidectomy at the earliest stages of the C-cell disease. OBJECTIVE: To define reliable parameters by which to identify the best moment for thyroidectomy in patients who are carriers of the MEN 2 gene. PATIENTS AND METHODS: Seventy-one MEN 2/FMTC gene carriers, collected through the national register of the French Calcitonin Tumours Study Group, were evaluated. All the patients included were younger than 20 years of age and underwent total thyroidectomy. Basal and pentagastrin-stimulated calcitonin were assayed using an immunoradiometric method (sensitivity less than 2pg/ml). Calcitonin measurement was evaluated on the basis of histopathological findings in surgical thyroid specimens. RESULTS: We found C-cell hyperplasia or medullary thyroid carcinoma in all the 71 gene carriers - even for the youngest patients - and nodal metastases were present in four cases. Calcitonin measurement (basal or pentagastrin-stimulated) detected C-cell disease preoperatively in all patients. Six of the 71 patients were not surgically cured: one had nodal metastases, one had an advanced staged disease and four had an incomplete nodal dissection or had not undergone lymph node surgery. CONCLUSIONS: Determination of calcitonin forms an integral part of the management of MEN 2 gene carriers. Thyroidectomy is undisputably indicated when basal calcitonin is abnormal. When basal calcitonin is undetectable, a pentagastrin-stimulated increase in calcitonin to more than 10 pg/ml indicates an early thyroidectomy to cure the patient.


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
C. J. Wray, T. A. Rich, S. G. Waguespack, J. E. Lee, N. D. Perrier, and D. B. Evans
Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Ann. Surg. Oncol., January 1, 2008; 15(1): 293 - 301.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K Frank-Raue, H Buhr, H Dralle, E Klar, N Senninger, T Weber, S Rondot, W Hoppner, and F Raue
Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
Eur. J. Endocrinol., August 1, 2006; 155(2): 229 - 236.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
G. Szinnai, C. Meier, P. Komminoth, and U. W. Zumsteg
Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis
Pediatrics, February 1, 2003; 111(2): e132 - 139.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. Burke
Genetic Testing
N. Engl. J. Med., December 5, 2002; 347(23): 1867 - 1875.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Lombardo, E. Baudin, E. Chiefari, F. Arturi, S. Bardet, B. Caillou, C. Conte, B. Dallapiccola, D. Giuffrida, J.-M. Bidart, et al.
Familial Medullary Thyroid Carcinoma: Clinical Variability and Low Aggressiveness Associated with RET Mutation at Codon 804
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1674 - 1680.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al.
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5658 - 5671.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Niccoli-Sire, A. Murat, V. Rohmer, S. Franc, G. Chabrier, L. Baldet, B. Maes, F. Savagner, S. Giraud, S. Bezieau, et al.
Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3746 - 3753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.